JP2011512415A - 癌の治療および予防のための治療用ペプチドの使用 - Google Patents

癌の治療および予防のための治療用ペプチドの使用 Download PDF

Info

Publication number
JP2011512415A
JP2011512415A JP2010547751A JP2010547751A JP2011512415A JP 2011512415 A JP2011512415 A JP 2011512415A JP 2010547751 A JP2010547751 A JP 2010547751A JP 2010547751 A JP2010547751 A JP 2010547751A JP 2011512415 A JP2011512415 A JP 2011512415A
Authority
JP
Japan
Prior art keywords
amino acid
acid residues
cancer
replaces
muc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010547751A
Other languages
English (en)
Japanese (ja)
Inventor
ジョイス エー． シュロエダー
Original Assignee
アリゾナ バイオメディカル リサーチ コミッション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゾナ バイオメディカル リサーチ コミッション filed Critical アリゾナ バイオメディカル リサーチ コミッション
Publication of JP2011512415A publication Critical patent/JP2011512415A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010547751A 2008-02-20 2009-02-19 癌の治療および予防のための治療用ペプチドの使用 Pending JP2011512415A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3002108P 2008-02-20 2008-02-20
PCT/US2009/034541 WO2009105557A1 (en) 2008-02-20 2009-02-19 Use of therapeutic peptides for the treatment and prevention of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014174796A Division JP2015028034A (ja) 2008-02-20 2014-08-29 癌の治療および予防のための治療用ペプチドの使用

Publications (1)

Publication Number Publication Date
JP2011512415A true JP2011512415A (ja) 2011-04-21

Family

ID=40848240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010547751A Pending JP2011512415A (ja) 2008-02-20 2009-02-19 癌の治療および予防のための治療用ペプチドの使用
JP2014174796A Pending JP2015028034A (ja) 2008-02-20 2014-08-29 癌の治療および予防のための治療用ペプチドの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014174796A Pending JP2015028034A (ja) 2008-02-20 2014-08-29 癌の治療および予防のための治療用ペプチドの使用

Country Status (8)

Country Link
US (2) US20110014195A1 (enExample)
EP (1) EP2247301B1 (enExample)
JP (2) JP2011512415A (enExample)
CN (1) CN101977623A (enExample)
AU (1) AU2009215503B2 (enExample)
CA (1) CA2714939A1 (enExample)
ES (1) ES2500640T3 (enExample)
WO (1) WO2009105557A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585938B2 (en) 2010-10-12 2017-03-07 Arizona Cancer Therapeutics, Llc EGFR-based peptides
WO2016161440A2 (en) 2015-04-03 2016-10-06 Arizona Cancer Therapeutics, Llc Egfr-based inhibitor peptides for combinatorial inactivation of erbb1, erbb2, and erbb3
CN110305209B (zh) * 2019-07-09 2022-09-13 福建医科大学附属第一医院 用于治疗恶性肿瘤的多肽及其作为疫苗的用途
WO2022173917A1 (en) * 2021-02-11 2022-08-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating breast cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005510200A (ja) * 2000-12-22 2005-04-21 ダナ−ファーバー　キャンサー　インスティテュート，インコーポレイテッド Ｍｕｃ１による細胞増殖調節方法
WO2006113667A1 (en) * 2005-04-15 2006-10-26 University Of Arizona Therapeutic peptides for the treatment of metastatic cancer
JP2008500815A (ja) * 2004-03-19 2008-01-17 イムクローン システムズ インコーポレイティド ヒト抗上皮成長因子受容体抗体
JP2008503498A (ja) * 2004-06-17 2008-02-07 マンカインド コーポレイション 癌の診断及び免疫療法における腫瘍関連抗原プロファイル

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080090770A1 (en) * 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005510200A (ja) * 2000-12-22 2005-04-21 ダナ−ファーバー　キャンサー　インスティテュート，インコーポレイテッド Ｍｕｃ１による細胞増殖調節方法
JP2008500815A (ja) * 2004-03-19 2008-01-17 イムクローン システムズ インコーポレイティド ヒト抗上皮成長因子受容体抗体
JP2008503498A (ja) * 2004-06-17 2008-02-07 マンカインド コーポレイション 癌の診断及び免疫療法における腫瘍関連抗原プロファイル
WO2006113667A1 (en) * 2005-04-15 2006-10-26 University Of Arizona Therapeutic peptides for the treatment of metastatic cancer

Also Published As

Publication number Publication date
AU2009215503A1 (en) 2009-08-27
CA2714939A1 (en) 2009-08-27
WO2009105557A1 (en) 2009-08-27
US20110014195A1 (en) 2011-01-20
EP2247301B1 (en) 2014-06-11
JP2015028034A (ja) 2015-02-12
CN101977623A (zh) 2011-02-16
US20160082082A1 (en) 2016-03-24
EP2247301A1 (en) 2010-11-10
ES2500640T3 (es) 2014-09-30
AU2009215503B2 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
Tandon et al. Emerging strategies for EphA2 receptor targeting for cancer therapeutics
Blanco-Aparicio et al. Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth
TWI577695B (zh) 用於輔助及先導性輔助療法之血管內皮生長因子（ｖｅｇｆ）-特異性拮抗劑及早期腫瘤之治療
JP5116663B2 (ja) 転移癌の処置のための治療用ペプチド
Basavaraj et al. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR
US9316654B2 (en) TAZ/WWTR1 for diagnosis and treatment of cancer
Lee et al. Inhibition of breast cancer growth and metastasis by a biomimetic peptide
Raven et al. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation
Tang et al. Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2/β-catenin positive feedback loop
JP5756014B2 (ja) がんの診断および治療のためのｖｈｚ
JP2015028034A (ja) 癌の治療および予防のための治療用ペプチドの使用
Chen et al. Normal cells repel WWOX-negative or-dysfunctional cancer cells via WWOX cell surface epitope 286-299
Cook et al. Ubiquitous Brms1 expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis
Wan et al. Cell-cell interactions in the oral mucosa: tight junctions and gap junctions
WO2002055109A2 (en) Generation and/or reduction of new lung tissue in an affected lung, by modulation of the wnt-pathway
TWI609692B (zh) 新穎ｓｔｉｐ１多肽及其用途
Sweeney et al. ErbB receptor negative regulatory mechanisms: implications in cancer
Campbell et al. ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis
EP3846799A1 (en) Combined therapy inhibiting expression, activity and/or function of epidermal growth factor receptor and c-raf against cancer
Xu et al. SALL4-targeted therapeutic peptide PEN-FFW suppresses PD-L1 and enhances CD8⁺ T cell cytotoxicity via regulating PI3K/AKT signaling in breast cancer
Peng et al. TGF-β1/SMAD3-mediated non-canonical hedgehog signaling promotes pancreatic stellate cell activation and fibrosis in chronic pancreatitis
Kedinger et al. Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis
US20250134975A1 (en) Cancer vaccine comprising epitope of c-met and use thereof
Al Haitham Al Shetawi et al. Reconstruction of Head and Neck Melanoma
Wang THE ROLE OF HMGA1 IN PANCREATIC CARCINOGENESIS AND STROMA FORMATION

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131004

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140501

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140813